Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022116 (
ischemia
)
91,303
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Differential screening of gerbil brain hippocampal cDNA libraries was used to search for genes expressed in ischemic, but not normal, brain. The
methylmalonyl-CoA mutase
(
MCM
) cDNA was highly expressed after
ischemia
and showed a 95% similarity to mouse and 91% similarity to the human
MCM
cDNAs. Transient global
ischemia
induced a fourfold increase in
MCM
mRNA on Northern blots from both hippocampus and whole forebrain.
MCM
protein exhibited a similar induction on Western blots of gerbil cerebral cortex 8 and 24 hr after
ischemia
. Treatment of primary brain astrocytes with either the branched-chain amino acid (BCAA) isoleucine or the BCAA metabolite, propionate, induced
MCM
mRNA fourfold. Increased concentrations of BCAAs and odd-chain fatty acids, both of which are metabolized to propionate, may contribute to inducing the
MCM
gene during
ischemia
. Methylmalonic acid, which is formed from the
MCM
substrate methylmalonyl-CoA and which inhibits succinate dehydrogenase (SDH), produced dose-related cell death when injected into the basal ganglia of adult rat brain. This neurotoxicity is similar to that of structurally related mitochondrial SDH inhibitors, malonate and 3-nitropropionic acid. Methylmalonic acid may contribute to neuronal injury in human conditions in which it accumulates, including
MCM
mutations and B12 deficiency. This study shows that
methylmalonyl-CoA mutase
is induced by several stresses, including
ischemia
, and would serve to decrease the accumulation of an endogenous cellular mitochondrial inhibitor and neurotoxin, methylmalonic acid.
...
PMID:Methylmalonyl-CoA mutase induction by cerebral ischemia and neurotoxicity of the mitochondrial toxin methylmalonic acid. 892 40